Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. OpGen, Inc.
  6. News
  7. Summary
    OPGN   US68373L3078

OPGEN, INC.

(OPGN)
  Report
Delayed Nasdaq  -  04:00 2022-11-29 pm EST
0.1714 USD   +0.65%
11/14OpGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
11/10Transcript : OpGen, Inc., Q3 2022 Earnings Call, Nov 10, 2022
CI
11/10Opgen Inc : Results of Operations and Financial Condition, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Sector Update: Health Care Stocks Weaken With Broader Markets

09/30/2022 | 04:04pm EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BARCLAYS PLC 1.78% 161 Delayed Quote.-13.90%
ILLUMINA, INC. -3.84% 208.57 Delayed Quote.-42.98%
NASDAQ COMPOSITE -0.59% 10983.78 Real-time Quote.-28.24%
OPGEN, INC. 0.65% 0.1714 Delayed Quote.-82.97%
TEVA PHARMACEUTICAL INDUSTRIES LIMITED 0.70% 8.67 Delayed Quote.7.49%
VERASTEM, INC. 4.23% 0.4066 Delayed Quote.-80.17%
All news about OPGEN, INC.
11/14OpGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Septem..
CI
11/10Transcript : OpGen, Inc., Q3 2022 Earnings Call, Nov 10, 2022
CI
11/10Opgen Inc : Results of Operations and Financial Condition, Change in Directors or Principa..
AQ
11/10Earnings Flash (OPGN) OPGEN Posts Q3 Revenue $448.7M
MT
11/10OpGen, Inc. Reports Goodwill Impairment Charge for the Third Quarter Ended September 30..
CI
11/10OpGen, Inc. Appoints Yvonne Schlaeppi as Independent Director and Member of Audit Commi..
CI
11/10OpGen Reports Third Quarter 2022 Financial Results and Provides Business Update
GL
11/10OpGen, Inc. Provides Revenue Guidance for the Year 2022
CI
11/01Opgen : Corporate Presentation
PU
10/27OpGen Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2022 ..
GL
More news
Analyst Recommendations on OPGEN, INC.
More recommendations
Financials (USD)
Sales 2022 3,55 M - -
Net income 2022 -24,5 M - -
Net Debt 2022 5,18 M - -
P/E ratio 2022 -0,35x
Yield 2022 -
Capitalization 9,20 M 9,20 M -
EV / Sales 2022 4,05x
EV / Sales 2023 4,89x
Nbr of Employees 95
Free-Float 99,5%
Chart OPGEN, INC.
Duration : Period :
OpGen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPGEN, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 0,17 $
Average target price 1,58 $
Spread / Average Target 822%
EPS Revisions
Managers and Directors
Oliver Schacht President, Chief Executive Officer & Director
Albert Weber Chief Financial Officer & Secretary
William E. Rhodes Non-Executive Chairman
Faranak Atrzadeh Chief Marketing & Scientific Affairs Officer
Johannes Bacher Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
OPGEN, INC.-82.97%9
MODERNA, INC.-30.95%67 378
IQVIA HOLDINGS INC.-24.68%39 832
LONZA GROUP AG-34.32%39 180
ALNYLAM PHARMACEUTICALS, INC.20.76%25 738
SEAGEN INC.-24.08%22 506